| INTRODUCTION
Primary sclerosing cholangitis (PSC) causes chronic and progressive injury to the bile ducts characterised by inflammatory and obliterative periductal fibrosis, and is the classic hepatobiliary extra-intestinal manifestation of inflammatory bowel disease (IBD). 1 With disease progression, progressive biliary strictures can lead to cholangitis, biliary cirrhosis and end-stage liver disease. 1 Two-thirds of cases of PSC cases are associated with IBD 2 and, although patients are commonly asymptomatic at the time of diagnosis, they have a shorter than average survival compared to matched controls in the general population. 3, 4 As PSC is associated with significant morbidity and mortality, various therapies have been examined in an effort to mitigate the progressive nature of the disease. Immunosuppressive agents including corticosteroids, tacrolimus, ciclosporin, azathioprine, methotrexate and anti-tumour necrosis factor (TNF) therapies have not shown clinical benefit in PSC. 3 Ursodeoxycholic acid, a hydrophilic bile acid that is often employed to treat cholestatic liver diseases, 3, 5 has demonstrated improvement in alkaline phosphatase and other liver biochemistry in patients with PSC but has not favourably influenced key endpoints that include death, liver transplantation or progression to cirrhosis. 1, 3, 6, 7 Vedolizumab is a selective humanised monoclonal antibody to the a 4 b 7 integrin expressed on lymphocytes. The binding of the a 4 b 7 integrin to MadCAM-1, which is expressed on intestinal endothelial vessels, allows for gut lymphocyte trafficking. 8 Thus vedolizumab modulates the ability of lymphocytes to enter the gastrointestinal epithelium, reducing inflammation and inducing mucosal healing in patients with moderate-severe Crohn's disease (CD) and ulcerative colitis (UC). [9] [10] [11] Although MAdCAM-1 is not expressed in normal liver tissue, it is induced in the portal tract endothelium of inflamed and cirrhotic livers, and its activity correlates with histological inflammatory activity in PSC. 12, 13 It has therefore been postulated that vedolizumab could also be of therapeutic benefit in patients with PSC. However, experience with vedolizumab in patients with PSC has been limited to individual-center case series. 14, 15 We studied the use of vedolizumab in a multi-centre, multinational cohort of patients with PSC and IBD with a primary focus on change in liver biochemistry. Secondary outcomes assessed for changes in prognostic models of PSC and clinical outcomes and safety of vedolizumab in patients with chronic liver disease and IBD including patients with orthotopic liver transplant.
| MATERIALS AND METHODS

| Participants
Electronic medical records at participating sites were reviewed for Hospital, Melbourne, Australia (n = 3). These sites were identified by a pre-existing collaborative group without prior knowledge to the number of patients that would meet the inclusion criteria. All patients that met the inclusion criteria from each site were included in the study. Institutional review board approval was granted at the individual participating sites.
| Study design
A retrospective cohort study was performed. In patients with baseline endoscopy and follow-up colonoscopy after at least 3 months of vedolizumab, endoscopic response was assessed utilising the SES-CD for CD patients 20 or Mayo endoscopic subscore for UC. 21 In CD, endoscopic improvement was defined as reduction in the SES-CD > 50% and mucosal healing as SES-CD score < 3. In UC, endoscopic improvement was defined as absolute reduction ≥ 1 point in the Mayo endoscopic subscore and mucosal healing as Mayo endoscopic subscore of 0 or 1. Biopsies in CD and UC were scored on a 4-point scale as quiescent/normal (0), mild (1), moderate (2) or severe (3). 22 Histological improvement was defined as an absolute reduction of 1 point or more and histological remission as score of 0.
| Statistical methods
Patients were analysed on an intent-to-treat basis and cessation of vedolizumab for any reason was considered treatment failure. At commencement of vedolizumab, 7 patients were on long-term ursodeoxycholic acid, the dose of which did not change in these patients throughout the study period. Two patients commenced ursodeoxycholic acid during the study period.
| Efficacy
| Alkaline phosphatase
Alkaline phosphatase levels from all patients with active PSC and biochemical testing before and after vedolizumab are shown in Table 2 and Figure achieved histological improvement and 1 (17%) histological remission ( Figure 4B ). There was no association between mucosal improvement and change in serum alkaline phosphatase activity, with 33% and 29% of those who had deterioration and improvement of their alkaline phosphatase, respectively, achieving endoscopic improvement with vedolizumab treatment (P = 1.00). 
| Safety and adverse events
27,28
Whether PSC itself is at all reversible is something that is yet to be determined. In this short-term study, we have relied on improvement in liver biochemistry to determine the utility of vedolizumab in patients with PSC. It is therefore presumed that, in part at least, the damage and increase in alkaline phosphatase in PSC is reversible. There were no other severe adverse events associated with vedolizumab use in this population, and the 12% of patients with minor adverse event were expected and similar as those reported in previous studies. 11, 30, 31 There are a number of notable limitations to this study. First, all data collection was performed retrospectively, but, since the included centres are all major referral centres for IBD and liver disease, we were able to collect data obtained from routine clinic visits.
Although we strengthened the data quality using objective outcome assessments where possible, there may still be bias present in the clinical follow-up of patients. Secondly, the sample size was small, which may have contributed, for example, to the failure to observe statistical significance in changes in liver biochemistry, particularly at week 30 outcomes where large interquartile ranges are observed. However, the absolute difference in the primary outcomes of alkaline phosphatase levels does not appear to be clinically significant even if larger patient numbers were able demonstrates a statistically significant difference. The small sample size, however, also did not allow comparison of liver biochemistry improvement between different sub-groups including those with intra versus extrahepatic PSC or history of liver transplant to be adequately explored. The patients included in this study were also more likely to have CD than UC which is not reflective of the ratios of CD versus UC in the general PSC population. This is likely secondary to the fact that at the time of this study vedolizumab was primarily used to treat the intestinal disease activity rather than the PSC and in some centres, including the University of Chicago, the majority of patients commenced on vedolizumab had CD. 30, 38, 39, 40 There is also the possibility that changes in ALP were secondary to other causes like low vitamin D status. Unfortunately, vitamin D levels were not assessed in this study but it is felt the likelihood of this altering the results significantly is low as all patients were treated at large academic centres where Vitamin D levels are routinely assessed and aggressively replaced. Finally, this study is limited by its short duration of followup. Changes in liver biochemistries were only assessed to week 30 of therapy and, therefore, longer term outcomes such as need for liver transplantation, development of cirrhosis or cancer incidence were unable to be assessed. Clearly larger, prospective, multi-centre studies are required to look at this question in more detail.
In conclusion, our study did not demonstrate sustained improve- 
